Search VIR
Vir Biotechnology, Inc.
Nasdaq · CIK 1706431
Last close11.17
Daily change-0.12 (-1.06%)
10 Years gain-20.33%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
VIR · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
38.7Momentum
n/aAcceleration
n/aConfidence
64.0Annual Revenue9
Quarterly Revenue35
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.7 / 25
Quality14.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM270.58%OK
Revenue CAGR 3Y-65.12%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $68.56M | $68.53M | -$479.33M | -$391.78M | -$396.61M | 99.96% | -699.18% | -578.52% | -136.77% | 138.52M |
| 2025 FY Dec 31, 2024 | $74.21M | $73.36M | -$587.17M | -$446.35M | -$453.65M | 98.86% | -791.27% | -611.35% | -283.65% | 136.25M |
| 2025 FY Dec 31, 2023 | $86.18M | $83.42M | -$684.31M | -$778.79M | -$800.36M | 96.79% | -794.04% | -928.71% | n/a | 134.13M |
| 2024 FY Dec 31, 2022 | $1.62B | $1.47B | $833.07M | $1.66B | $1.60B | 90.94% | 51.56% | 98.73% | 198.28% | 134.81M |
| 2023 FY Dec 31, 2021 | $1.10B | $1.03B | $420.75M | -$47.59M | -$69.41M | 93.99% | 38.41% | -6.34% | 95.53% | 133.44M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $240.37M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-25-038431, 0001628280-25-049694 |
| Revenue Growth TTM | 270.58% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-25-038431, 0001628280-25-049694 |
| Revenue CAGR 3Y | -65.12% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-010749 |
| Revenue CAGR 5Y | -2.14% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-010749 |
| Gross Profit CAGR 3Y | -64.01% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-010749 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-053549 |
| Current Ratio | 6.04x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.42 | Revenue / Diluted Shares | OK | 0001628280-25-038431, 0001628280-25-049694 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001628280-26-010749 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001628280-26-053549 |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |